Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
Posted: June 13, 2022 at 2:35 am
Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1
Read more here:
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
Posted in Global News Feed
Comments Off on Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022
Posted: June 13, 2022 at 2:35 am
REGULATED INFORMATION
More:
Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022
Posted in Global News Feed
Comments Off on Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Posted: June 13, 2022 at 2:35 am
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Follow this link:
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Posted in Global News Feed
Comments Off on Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
Posted: June 13, 2022 at 2:35 am
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol.
More:
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
Posted in Global News Feed
Comments Off on Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody…
Posted: June 13, 2022 at 2:35 am
Marseille, France, June 13, 2022 – ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million - USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million - USD 17.2 Million) solidifies ImCheck’s financial position and leadership in the gamma-delta T cell space. Invus and The Leukemia & Lymphoma Society Therapy Acceleration Program® also joined the round as new investors. Existing investors including the Growth Opportunity Fund of founding investor Kurma Partners, Eurazeo, Gimv, EQT Life Sciences (previously LSP), Boehringer Ingelheim Venture Fund, Pfizer Ventures, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Agent Capital, Pureos Bioventures and Alexandria Venture Investments participated.
Posted in Global News Feed
Comments Off on ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody…
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Posted: June 4, 2022 at 2:45 am
Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies
See original here:
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Posted in Global News Feed
Comments Off on Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
Posted: June 4, 2022 at 2:45 am
Rescheduled to June 16, 2022, at 1:00pm Eastern Time Rescheduled to June 16, 2022, at 1:00pm Eastern Time
More here:
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
Posted in Global News Feed
Comments Off on Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
Zealand Pharma to Participate in Upcoming Investor Conferences
Posted: June 4, 2022 at 2:45 am
Press release – No. 3/ 2022
Read the original:
Zealand Pharma to Participate in Upcoming Investor Conferences
Posted in Global News Feed
Comments Off on Zealand Pharma to Participate in Upcoming Investor Conferences
OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and…
Posted: June 4, 2022 at 2:45 am
Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60%
Posted in Global News Feed
Comments Off on OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and…
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Posted: June 4, 2022 at 2:45 am
New York, NY, and Tel Aviv, ISRAEL, June 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its academic partner, Dr. Thomas Arendt at Leipzig University, has completed full enrollment for 2nd cohort (confirmatory) for the ongoing clinical trial to evaluate the concordance of the LymPro Alzheimer’s Blood Test scores with amyloid PET imaging scores. The Company expects the data to be released in the summer of 2022.
See the rest here:
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Posted in Global News Feed
Comments Off on Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET